Ilumya Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of topical psoriasis treatments, rising prevalence of chronic plaque psoriasis, early biologic dermatology approvals, dermatologist driven biologic adoption, patient demand for durable clearance.

The growth in the forecast period can be attributed to increasing biologic penetration in dermatology, growth in systemic psoriasis therapies, expanding insurance coverage for biologics, advancements in cytokine selective treatments, rising patient adherence programs. Major trends in the forecast period include growth of il-23 inhibitor adoption, shift toward long acting psoriasis therapies, rising demand for biologic dermatology treatments, improved dosing convenience, expansion of moderate to severe psoriasis care.

The growing prevalence of psoriasis is expected to drive the growth of the Ilumya market. Psoriasis is a long-term autoimmune condition that accelerates skin cell growth, leading to red, scaly patches on the skin. The increasing prevalence of psoriasis can be attributed to factors such as better diagnosis and awareness, environmental influences, genetic predisposition, obesity, and the impact of certain medications and infections. Ilumya is essential in treating psoriasis as it helps reduce inflammation and slow the overproduction of skin cells by targeting interleukin-23 (IL-23), effectively managing the symptoms of moderate to severe plaque psoriasis. For example, in May 2023, a report published by the National Library of Medicine (NLM), a US-based medical library, predicted an increase in the incidence and disability-adjusted life years (DALY) of psoriasis among individuals aged 30-39 by 2030. As a result, the growing prevalence of psoriasis is contributing to the growth of the Ilumya market.

The increasing healthcare expenditure is expected to drive the growth of the Ilumya market. Healthcare expenditure refers to the total spending on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. The rise in healthcare expenditure is driven by factors such as an aging population, the growing prevalence of chronic diseases, and higher demand for healthcare services. Expenditure on Ilumya specifically focuses on advanced treatments for moderate-to-severe plaque psoriasis, targeting interleukin-23 (IL-23). For instance, in May 2024, a report from the Office for National Statistics, a UK-based government department, revealed that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared to a growth of only 0.9% in 2022. As a result, the rising healthcare expenditure is further fueling the growth of the Ilumya market.

The rising funding for clinical trials is also expected to propel the growth of the Ilumya market. Clinical trial funding refers to financial resources allocated to support research studies that assess the safety, efficacy, and potential of new medical treatments and interventions. The increase in clinical trials funding is driven by the growing recognition of the need for innovative therapies to address unmet medical needs in chronic inflammatory conditions, as well as the commitment from governments and organizations to advance medical research. Ilumya benefits from clinical trials funding by enabling comprehensive research into biologic therapies for moderate-to-severe plaque psoriasis, supporting evidence-based treatment protocols, and facilitating the development of next-generation dermatological solutions. For example, in December 2024, The Association of the British Pharmaceutical Industry, a UK-based organization, reported that the number of industry-sponsored clinical trials initiated in the UK rose from 411 in 2022 to 426 in 2023, supporting the development of new treatments and generating additional revenue for the NHS. Therefore, the growing funding of clinical trials is further driving the growth of the Ilumya market.

Major companies operating in the ilumya market are Sun Pharmaceutical Industries Ltd.

North America was the largest region in the ilumya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ilumya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ilumya market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the ilumya market by raising costs related to biologic drug production, sterile filling operations, and global distribution logistics. These effects are most significant in hospital and specialty clinic channels, particularly in regions dependent on imported dermatology biologics. Increased tariffs may affect treatment affordability and delay uptake in cost sensitive healthcare systems. At the same time, tariffs are encouraging regional manufacturing expansion, supply chain optimization, and localized packaging strategies to ensure sustained access to psoriasis biologics.

The ilumya market research report is one of a series of new reports that provides ilumya market statistics, including ilumya industry global market size, regional shares, competitors with a ilumya market share, detailed ilumya market segments, market trends and opportunities, and any further data you may need to thrive in the ilumya industry. This ilumya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ilumya is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy (ultraviolet light treatment). It is a monoclonal antibody that targets interleukin-23 (IL-23), a cytokine involved in inflammation and the overproduction of skin cells associated with psoriasis. By inhibiting IL-23, Ilumya helps reduce inflammation and slow the rapid turnover of skin cells, improving symptoms of psoriasis such as plaques, scaling, and redness.

The main patient demographics for Ilumya include pediatric and adult patients. Pediatric patients are individuals under the age of 18 who require specialized care for various health conditions. Ilumya is distributed through hospitals, specialty clinics, online pharmacies, and retail pharmacies, and is used to treat plaque psoriasis, psoriatic arthritis, and other inflammatory conditions.

The ilumya market consists of sales of biologics and biosimilars, dermatology products, and generic pharmaceuticals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.